ROC analysis indicated that circEGLN3 allowed the most accurate discrimination of ccRCC and NAT (AUC = 0.879; sensitivity 87.1%, specificity 77.8%) followed by circEHD2 (AUC = 0.757; sensitivity 52.5%, specificity 85.2%) and circNETO2 (AUC = 0.705; sensitivity 59.4%; specificity 82.7%); see Figure 2. The gene discussed is BRD2; the disease is nonpapillary renal cell carcinoma.